Siva Therapeutics Selected as a Company to Watch at the Angel Capital Summit in Denver, CO

BOULDER, COLORADO, April 4, 2012–Siva Therapeutics was selected as a company to watch by a panel of investors at the Angel Capital Summit (ACS) in Denver, CO. Out of 40 presenting companies, Siva Therapeutics was one of 13 companies selected to the watch list by investors during the Denver Investor Forum that took place following the ACS presentations. Continue reading

Siva Therapeutics Inc will present at the Angel Capital Summit in Denver, CO

BOULDER, COLORADO, March 20, 2012– Siva Therapeutics announced today it has been selected topresent at the Angel Capital Summit held at the University of Denver. The Angel Capital Summit is athree day event at the University of Denver designed to connect investors with entrepreneurs. Theevent contains workshops for entrepreneurs, speakers, investor forums, and popular networking events. Continue reading

Biotech Industry CFO Joins Siva Therapeutics Management Team

BOULDER, COLORADO, January 3, 2012 – Siva Therapeutics announced today that Colin Shepherd, PhD, MBA, has joined its management team as CFO. Dr. Shepherd has served in a number of diverse roles in his biotechnology career, most recently as COO and interim CEO of Madison, Wisconsin, based PhylloTech LLC. Prior to PhylloTech, he founded AimsBio LLC, a agricultural analytics service provider that provides high throughput analytics to the agricultural industry. Dr. Shepherd received a BS in Agricultural Biotechnology from the University of Kentucky (Lexington, KY), a PhD in Genetics from Iowa State University (Ames, IA), and an MBA from Iowa State University (Ames, IA) Continue reading

Siva Therapeutics to Present at the 2011 Rocky Mountain Life Science Investor and Partnering Conference

BOULDER, COLORADO, September 1, 2011 – Siva Therapeutics is one of 30 emerging companies selected to present at the upcoming Rocky Mountain Life Science Investor and Partnering Conference in Denver from September 21st to 23rd, 2011. This event provides exposure for Siva to the local and national investment community, and will assist Siva in raising $2.2 million to take R&D operations through the next phase of work. Continue reading

Siva Therapeutics Inc and NanoRods LLC Partner for Uses of Gold Nanorod Technology and Cancer Therapy

BOULDER, COLORADO, June 28, 2011Siva Therapeutics announced today signing of a broad license agreement with NanoRods LLC for the use of gold nanorods in cancer therapy. As part of the agreement, Siva will gain an exclusive license, for applications in cancer therapy, to NanoRods’ strong and growing patent portfolio. Continue reading